Huaxin Pharmaceutical (301096.SZ) plans to invest 15 million yuan in a partnership enterprise in Hangzhou to expand into strategic emerging industries such as biopharmaceuticals and advanced technology.

Smart Finance News App, Basheng Pharmaceuticals (301096.SZ) announced that the company plans to participate in the subscription of shares of Xihu Chuangxin (Hangzhou) Technology Innovation Transformation Entrepreneurship Investment Partnership Enterprise (Limited Partnership) through Hangzhou Mipeng Enterprise Management Partnership Enterprise (referred to as "Hangzhou Mipeng") controlled by the company. Hangzhou Mipeng signed the "Partnership Agreement" on September 19, 2025. As a limited partner, Hangzhou Mipeng plans to subscribe to the corresponding contribution amount with its own funds of 15 million yuan. The investment target of the partnership enterprise is to carry out entrepreneurial investment activities for enterprises in strategic emerging industries such as biomedicine, hard technology, and focus on investment opportunities for early-stage, small and medium-sized, and growth-stage enterprises.